Abbreviations: ANC = absolute neutrophil count; HMT = hypomethylating treatment; IPSS = international prognostic scoring system; MAC = myeloablative conditioning; MUD = matched unrelated donor; MSD = matched sibling donor; RARS = refractory anemia with ringed sideroblasts; RAEB = refractory anemia with excess blast; RBC = red blood cell; RCMD = refractory cytopenia with multilineage dysplasia; RIC = reduced-intensity conditioning; SCT = stem cell transplantation; WBC = white blood cell; WHO = World Health Organization.
Recent molecular studies identified genetic mutations in myelodysplastic syndrome (MDS) and their associations with clinical parameters. 1, 2 As an increasing number of recurrent somatic mutations have been found, many investigators are focusing on genetic mutations as candidate molecular markers for MDS prognosis and treatment outcomes, especially following hypomethylating treatment (HMT) or stem cell transplantation (SCT). In this study, we analyzed recurrent TET2, TP53, ETV6, RUNX1, EZH2, ASXL1, SF3B1, U2AF1 and SRSF2 mutations, which are relatively frequent, and their influence on survival was reported independently of clinical parameters. 2, 3 Fifty-two patients receiving HMT and/or SCT for MDS at our institution from April 2009 to May 2011 were retrospectively analyzed. Median age of the patients was 52 years (range, 18-73 years), and 36 (69.1%) patients were male. Clinical and disease characteristics are summarized in Table 1 . Treatment strategies followed the institution's guideline elsewhere reported, 4 and initial treatment was with HMA in 43 patients, SCT in 8 patients and intensive chemotherapy in 1 patient. SCT was immediately planned whenever possible for patients with the higher-risk (Hr, intermediate-2/high by international prognostic scoring system) group, but planned for the lower-risk (Lr, low/intermediate-1 by international prognostic scoring system) group with life-threatening cytopenia or HMT failure. 5, 6 Forty-three patients received a median of four cycles (range, 1-29) of azacitidine (n = 24) or a median of two cycles (range, 1-5) of decitabine (n = 19), and responses were assessed using standard criteria. 7 Forty patients received PBSCT after conditioning with fludarabine (150 mg/m 2 ), IV busulfan (12.8 or 6.4 mg/kg) and rabbit ATG (5 or 10 mg/kg). Fractionated totalbody irradiation (800 cGy) was added for haploidentical SCT. Mutation analyses were performed using bone marrow genomic DNAs. Mutations in nine genes were evaluated by Sanger sequencing using the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) using primers designed with Primer 3 (Supplementary Table 1 ). SF3B1, U2AF1 and SRSF2 mutational data reported previously were used. 8 Thirty-three patients (63.5%) had mutations in one or more genes (Supplementary Table 2 ). ASXL1 was the most frequently mutated gene (n = 13, 25.0%), followed by U2AF1 (n = 11, 21.2%), TET2 (n = 8, 15.4%), RUNX1 (n = 7, 13.5%), SRSF2 (n = 5, 9.6%), EZH2
(n = 4, 7.7%), TP53 (n = 4, 7.7%), SF3B1 (n = 3, 5.8%) and ETV6 (n = 2, 3.8%). Eighteen patients (57.6%) had more than two genetic mutations; 4 patients (15.2%) had mutations in three genes; 14 patients (42.4%) had mutations in two genes; and 14 patients (42.4%) had mutations in one gene. Thirty patients (57.7%) revealed abnormal karyotype and 56.7% (17/30) of them demonstrated genetic mutations. Sixteen patients with normal karyotype (72.7%, 16/22) had genetic mutations. Therefore, 88.5% (46/52) of the enrolled MDS patients were accompanied with genetic aberrations.
Next, we tried to define the clinical significance of these mutations. After a median follow-up of 40.8 months (95% confidence interval (CI), 35.8-45.7) for survivors, 24 patients survived, and the overall survival (OS) rate at 3 years after initial treatment was 52.0%. Among clinical parameters, age, risk group, sex and undergoing SCT were identified as potential prognostic factors for OS in a univariate analysis. Patients o 52 years (69.2% vs 452 years 35.6%, P = 0.026) and those receiving SCT (60.4% vs no SCT 25.0%, P = 0.016) had a significantly better OS rate. A trend for better survival was observed in the Lr group (64.4% vs Hr group 41.7%, P = 0.072) and in female individuals (75.0% vs 41.9% for male individuals, P = 0.081). In contrast, RBC transfusion dependency (P = 0.236), hemoglobin o10 g/dL (P = 0.139), ANC o800 × 10 6 /L (P = 0.860) and platelets o100 × 10 9 /L (P = 0.108) were not associated with survival. Patients with mutations in any of the nine genes showed poor survival compared with those without mutations (44.0% vs 67.1%), but it did not reach statistical significance. A significantly poor survival rate was observed in Letter to the Editor TET2 and TP53 mutated patients (25.0% vs 56.8%, P = 0.012; 0% vs 56.4%, P = 0.002, respectively, Figure 1a and b). Patients with at least one of the TET2 and TP53 gene mutations (TET2/TP53, n = 11) showed significantly poor 3-year survival (18.2% vs none 61.1%, Po 0.001, Figure 1c) . The multivariate analysis showed that the TET2/TP53 mutation (hazard ratio (HR), 7.6; 95% CI, 2.7-21.0, Po 0.001), Hr group (HR, 5.1; 95% CI, 1.8-14.7; P = 0.003) and not receiving SCT (HR, 3.6; 95% CI, 1.4-9.2, P = 0.003) were independent prognostic factors for OS. We then assessed the influence of the mutation on survival after SCT by analyzing 40 patients with or without previous treatment. The TET2/TP53 mutation was a poor prognostic factor (28.6% vs no mutation 68.1%, P = 0.011, Figure 1d) . A multivariate analysis determined that the TET2/TP53 mutation (HR, 4.4; 95% CI, 1.3-14.4, P = 0.016), Hr group (HR, 4.6; 95% CI, 1.0-14.7, P = 0.049) and HMT failure (HR, 4.4; 95% CI, 1.2-16.4, P = 0.027) were independent prognostic factors for OS in patients who received SCT (Supplementary Table 3 ). The number of these three unfavorable factors showed different 3-year OS rates (no unfavorable factor 100%, one unfavorable factor 77.1%, two unfavorable factors 33.3%, three unfavorable factors 0%, P o0.001). Transplant-related mortality occurred in 5 of 33 (15.1%) patients without TET/TP53 mutation and 3 of 7 (42.6%) patients with the mutation, and cumulative incidence of transplant-related mortality at 3 years was 27.3% and 58.3% (P = 0.026). Frequency of relapse was similar between the groups (no mutation, 7/33, 21.2% vs mutation, 2/7, 28.6%), and seven patients (five without the mutation and two with the mutation) died of relapse.
The frequency of mutations identified in this study was similar to those reported in other MDS patient cohorts. 9 TP53 gene mutations, which are found in 5-15% of patients with de novo MDS and more frequently in patients undergoing therapy-related MDS, are associated with an advanced clinical phenotype, a complex karyotype and disease progression.
10 TET2 gene mutations have been identified in 19-26% of MDS patients, and they do not have a strong predictive correlation with clinical outcome in MDS. Recent multigene analysis similarly identified TET2 mutations as predictive of response to HMT. 9 EZH2, ETV6, RUNX1 and ASXL1 have also been associated with poor survival. 2 SRSF and U2AF1 mutations are associated with the risk of AML transformation or shortened survival, 11, 12 whereas the SF3B1 mutation favors survival. 13, 14 Compared with these studies, our results show that mutations in the genes (ETV6, RUNX1, EZH2, ASXL1, U2AF1 and SRSF2) were not associated with survival. We assumed that active treatment given in our cohort might negate the unfavorable influences of mutations in these genes. We demonstrated that the TET2/TP53 mutation was an independent predictor for inferior survival in patients requiring HMT or SCT. The impact of genetic mutations on survival after SCT for MDS was recently reported by Bejar et al. 15 In their multivariate analysis, mutations in TP53 (HR, 4.22; P ⩽ 0.001) and TET2 (HR, 1.68; P = 0.037) were each independently associated with shorter OS. We obtained the same result, and our analyses suggested the need for evaluating the mutational status of at least the TET2 and TP53 genes when considering and designing SCT for MDS.
The relatively small number of patients, selection bias and heterogeneity of the treatment courses are limitations of our study. However, variations in the combination of HMA and SCT might be inevitable in real-world practice of patients requiring active treatment, as in our study. As patients were enrolled in our study based only on sample availability, our observations may reflect real practice with minimal selection bias. Although we are still cautious in making any definitive conclusion, our data suggest that disease reassessment using TP53 and TET2 mutational status at the time of HMA or SCT is valuable for predicting survival, but it requires further confirmatory study in a larger cohort.
